
|Articles|March 6, 2006
Matching up treatments for chronic schizophrenia is a challenge
The pharmacologic options available for the treatment of schizophrenia have never been greater. Yet, clinicians face difficult choices when selecting antipsychotics as they weigh the drugs' risks and benefits. This dilemma was underscored recently when a federally funded study found that of five agents, the most efficacious one, olanzapine (Zyprexa, Lilly), also caused the most weight gain and metabolic changes that could lead to diabetes or heart disease.
Advertisement
Newsletter
Pharmacy practice is always changing. Stay ahead of the curve with the Drug Topics newsletter and get the latest drug information, industry trends, and patient care tips.
Advertisement
Related Content
Latest CME
Advertisement
Advertisement
Trending on Drug Topics
1
Pneumococcal Diseases Require Constant Vaccine Development | NCPA 2025
2
FDA Approves Oral Semaglutide for Risk of MACE for Patients With Diabetes
3
How Personalized Supplement Counseling Can Drive Pharmacy Revenue | NCPA 2025
4
Pharmacist-Led Education is the Most Effective Supplement Marketing Strategy | NCPA 2025
5